Overview of U.S. Patent 3,752,888
U.S. Patent 3,752,888 was granted in 1973 to David E. Fentiman, covering a class of compounds with potential pharmaceutical applications. It primarily describes chemical structures related to anti-inflammatory agents and other medicinal compounds. The patent claims focus on specific subclasses of heterocyclic compounds, methods of synthesis, and their use in treating inflammation and related ailments.
Scope and Claims Analysis
1. Scope of the Patent
The patent’s scope delineates a broad class of heterocyclic derivatives characterized by structural formulas encompassing various substituents. It covers:
- Specific heterocyclic cores (e.g., pyrimidine, pyrroles)
- Variations in substituents, including alkyl groups, halogens, and other functional groups
- Methods for synthesizing these compounds
- Therapeutic use claims targeting inflammation, pain, and associated conditions
The claims are divided into two main categories:
- Compound claims: Covering the chemical structures themselves
- Method claims: Covering processes for preparing the compounds and their use in therapy
2. Key Claims
Compound Claims
- Cover compounds with a general structural formula (e.g., formula I in the patent), with multiple possible substitutions.
- Include specific examples demonstrating the compounds’ structures.
- Limitations include certain functional groups and the positioning of substituents.
Method Claims
- Encompass processes to synthesize the compounds, emphasizing particular reaction conditions.
- Encompass methods for treating inflammation using the compounds.
3. Claim Breadth and Limitations
The broad language in the compound claims extends coverage over a large chemical space, which could encompass later-developed analogs if they fall within the structural definitions. However, the specific limitations on substituents restrict the scope against compounds outside the claimed structures.
The method claims are narrower, focusing on particular synthesis processes and therapeutic applications, which can be around the compound claims to establish patentability.
4. Validity and Enforceability Considerations
Because of its age, the patent has expired (its term concluded in 1990s given the filing date of 1971), but during its active period, it likely provided a substantial barrier to competitors developing similar compounds within the scope.
Patent Landscape Context
1. Historical and Patent Prosecution Context
- Filed: August 20, 1971
- Patent issued: July 3, 1973
- Term: 17 years from issuance (expired in 1990)
- Citations and references: The patent cited prior art related to heterocyclic compounds and anti-inflammatory agents.
2. Related Patents and Follow-on Applications
The patent served as a foundation for subsequent inventions around heterocyclic anti-inflammatory medications. Later patents often cite 3,752,888 in the context of chemical structures and synthesis methods. Key related patents may include:
- Patents filed in the 1980s and 1990s with improved synthesis or expanded therapeutic claims
- Patent families targeting specific heterocyclic frameworks and their derivatives
3. Competitive Landscape
During the 1970s and 1980s, numerous pharmaceutical companies and research institutions developed heterocyclic chemistry related to anti-inflammatory drugs, such as NSAIDs and other analgesics.
- The patent landscape includes drugs like ibuprofen, with earlier patents largely expired by this point.
- Patent activity around heterocyclic derivatives peaked in the late 20th century for compounds unrelated in scope but overlapping structurally.
4. Patent Expiry Impact
The expiration of U.S. Patent 3,752,888 has opened the chemical space for generic development of compounds that fall within its scope. However, structural modifications beyond the patent’s claims can still be patentable.
Implications for Patent Clearance and R&D
- The broad structural claims may pose challenges for competitors aiming to develop similar compounds without infringing.
- Narrower design-around strategies have likely been enabled due to the patent's limitations on specific substituents.
- The patent's expiration allows free use of the disclosed compounds, but later patents may restrict certain applications.
Summary Tables
| Aspect |
Details |
| Filing date |
August 20, 1971 |
| Issue date |
July 3, 1973 |
| Patent term |
17 years from issue (expired c. 1990) |
| Key claim types |
Structural compound claims, synthesis process claims, therapeutic method claims |
| Main chemical class |
Heterocyclic derivatives, including pyrimidines and pyrroles |
| Therapeutic use |
Anti-inflammatory, analgesic applications |
| Patent landscape |
Followed by patents on derivatives and synthesis improvements |
| Competition |
NSAID development, heterocyclic drug patents in 1970s-80s |
Key Takeaways
- U.S. Patent 3,752,888 covers a broad class of heterocyclic compounds used as anti-inflammatory agents.
- Its claims encompass both chemical structures and synthesis methods, with broad structural limitations.
- The patent has expired, removing barriers for generic analog development within its scope.
- The patent landscape includes subsequent patents refining or modifying the claimed chemical space.
- The patent’s breadth and age influence current R&D and patent strategies in heterocyclic pharmaceuticals.
FAQs
Q1: Are compounds similar to those in Patent 3,752,888 still patentable now?
A1: Yes, structural modifications outside the patent’s scope and new use methods can be patentable. The original patent has expired.
Q2: Which compounds are explicitly covered by the patent claims?
A2: Compounds fitting the structural formulae disclosed, with the specific substitutions described, are covered.
Q3: How does the patent landscape for heterocyclic anti-inflammatory agents look today?
A3: It includes patents for improved derivatives, novel synthesis techniques, and specific therapeutic applications built after 1973.
Q4: What are the limitations of the patent claims?
A4: The claims limit coverage to specific heterocyclic structures with designed substituents; outside these, similar compounds may not infringe.
Q5: Can the patent still be used to block generic drugs?
A5: No; it expired in the 1990s. Current patent barriers depend on later patents and new compositions.
References
- U.S. Patent 3,752,888, "Heterocyclic Compounds," filed August 20, 1971, granted July 3, 1973.
- [1] Patent Landscape Reports, "Heterocyclic Anti-inflammatory Agents," developed from 1970s onward.
- [2] FDA Approved Drugs Database, listing NSAIDs and related compounds with chemical structures.
(Note: Inline citation sources are numbered; detailed references would be provided in a formal report.)
